Why the Resonance Health (ASX:RHT) share price is shooting 39% higher today

The Resonance Health Limited (ASX: RHT) share price is shooting 39% higher today after the company announced an important FDA clearance.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resonance Health Limited (ASX: RHT) share price is shooting the lights out today. This comes after the company announced it has received a 510(k) clearance from the United States Food and Drug Administration (FDA) for its HepaFat-AI software.

At the time of writing, the Resonance Health share price is up 38.7% to 21.5 cents. In comparison, the All Ordinaires Index (ASX: XAO) is up 0.7% to 6,969 points.

What's driving the Resonance Health share price?

The Resonance Health share price is surging today following the company's positive FDA clearance announcement.

According to Resonance Health, the FDA has cleared the pathway for the company to begin commercialisation for its HepaFat-AI technology.

HepaFat-AI is a medical imagining technology that uses artificial intelligence to assess liver fat. The software analyses volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF), and steatosis grade in individuals who suffer from fatty liver disease.

Once screened, a doctor or physician is able to explain the results to the patient which can, in turn, support them in weight loss management. In addition, the report can also evaluate if a person has a suitable liver for becoming a donor.

It is estimated that up to 30% of the world's population suffers from non-alcoholic fatty liver disease (NAFLD). This represents up to 2.3 billion people who face the possible risk of developing liver damage and fibrosis.

In financial terms, Resonance reported that over the next 10 years, the increasing incidence of NAFLD could cost the healthcare system $1 trillion in the United States alone. Furthermore, another 334 billion euros could expected to be sunk into treating the disease across Germany, France, Italy and the United Kingdom.

The company said that while there are currently a number of ways to measure liver fat, comparing results from different scan types is very difficult, with results highly variable. HepaFat-AI aims to improve on traditional testing measures by delivering a standardised assessment that allows for accurate comparisons across various scanner types. The company also highlighted that steatosis grading can be time consuming using other methods, however its software has automated the process, allowing for results to be produced much faster.

Resonance Health stated that it intends to pursue multiple channels to get HepaFat-AI to market.

What did management say?

Resonance Health CEO Ms Alison Laws commented on HepaFat-AI's applications and the result from the FDA. She said:

The use of artificial intelligence in medical image review and assessment has the ability to support and transform radiology via the delivery of rapid, reproducible results whenever needed. HepaFat-AI, the Company's second AI-based medical device to gain clearance from the FDA, will enable radiologists to report three key parameters (VLFF, PDFF, and steatosis grade) in patients in this significant and ever-increasing addressable market.

The clearance from the FDA to assess and report all three metrics in HepaFat-AI patient reports is an outstanding result for the Company and an outstanding result for the product itself.

Resonance Health share price summary

The Resonance Health share price has been on the rise since late September, delivering more than a 50% gain to shareholders. Resonance shares are, however, still 17% lower since the beginning of the year.

The Resonance share price reached a 52-week high of 28 cents in January and a 52-week low of 9.2 cents in March.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Resonance Health Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »

A woman puts her hands up as she smashes and breaks through a glass ceiling.
Share Gainers

How these 5 ASX 200 stocks are smashing the benchmark this week

These fives ASX 200 stocks have made some very happy shareholders this week. Here’s how.

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Catalyst Metals, Duratec, Nufarm, and Rio Tinto shares are dropping today

These shares are ending the week in the red. But why?

Read more »

A smiling woman at a hardware shop selects paint colours from a wall display.
Broker Notes

After its strategy day, what does Macquarie think Wesfarmers shares are worth?

Let's see what the broker is saying about this blue chip.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Technology Shares

After surging 13% yesterday, are TechnologyOne shares a buy, hold or sell according to Macquarie?

Valuations matter when investing, and Macquarie feels no different.

Read more »